Since IL-27 was first reported as having antitumor activity in animal models of colon cancer and neuroblastoma in 2004 (Hisada and others 2004; Salcedo and others 2004), the tumor-suppressive ability of IL-27 has been verified in various murine tumor models, including solid tumors as well as hematological malignancies (Oniki and others 2006; Murugaiyan and Saha 2013; Liu and others 2013). This evidence concerns the gene IL27 and colonic neoplasm.